Valeritas Holdings, Inc. announced additional data from the VERDICT study presented at the 19th Annual Diabetes Technology Meeting held in Bethesda, Maryland. This data demonstrated positive clinical outcomes for patients with type 2 diabetes who switched insulin therapy to V-Go from a basal-only, basal-bolus, or premix insulin regimen. This real-world retrospective analysis was performed using electronic medical records to identify 122 patients with uncontrolled type 2 diabetes (A1c > 7.0%) who switched to V-Go from traditional insulin injection therapy regimens. The study aimed to evaluate if the baseline insulin total daily dose (TDD) on the prior regimen influenced the effectiveness of V-Go. Patients were grouped based on their prior regimen TDD into three insulin strata: < 50 U/day, 50 to 100 U/day, or > 100 U/day to evaluate clinical outcomes. After a mean duration of five months of V-Go use, significant mean reductions in A1c of 1.3%; p<0.05 were observed for each strata. In addition, the strata prescribed higher baseline doses of insulin (50 to 100 U/day and > 100 U/day) benefited from a significant reduction in TDD of 19%; p<0.0001 and 47%; p<0.0001, respectively, after switching to V-Go. The number of patients reporting hypoglycemia decreased on V-Go.